Continued investigation into the underlying mechanisms of breast cancer has unveiled a variety of potential targets and novel treatments: mammalian target of rapamycin (mTOR); NTRK1, NTRK2, NTRK3; Cyclin D, Cyclin E; CDK4/6; B-Myb; Twist; DMP1β; TP53; FGFR, AKT1, AKT2, Src, PTEN, KRAS, APC, NF1, MAP2K4, MAP3K1, uPA, and PAI-1 [56,58,59,60,61,62,63,64,65,66]. This evidence concerns the gene MTOR and breast carcinoma.